Emi Kamiyama

633 total citations
22 papers, 476 citations indexed

About

Emi Kamiyama is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Emi Kamiyama has authored 22 papers receiving a total of 476 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Emi Kamiyama's work include HER2/EGFR in Cancer Research (11 papers), Drug Transport and Resistance Mechanisms (7 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Emi Kamiyama is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Drug Transport and Resistance Mechanisms (7 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Emi Kamiyama collaborates with scholars based in Japan, Germany and United States. Emi Kamiyama's co-authors include Daisuke Nakai, Masayuki Takahashi, Veronika Rozehnal, Satoru Yasuda, Juergen Mueller, Thomas M. Fischer, Daisuke Sugiyama, Osamu Okazaki, Toshihiko Ikeda and Zhuohan Hu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Emi Kamiyama

22 papers receiving 463 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emi Kamiyama Japan	11	295	110	85	82	71	22	476
Eric Y. Zhang United States	9	187 0.6×	76 0.7×	127 1.5×	60 0.7×	48 0.7×	11	425
Weili Huang China	10	173 0.6×	119 1.1×	308 3.6×	202 2.5×	78 1.1×	18	761
Reinhard Ding Germany	11	139 0.5×	109 1.0×	57 0.7×	88 1.1×	79 1.1×	13	403
Amanda Freeman United States	11	287 1.0×	73 0.7×	177 2.1×	80 1.0×	30 0.4×	13	748
Jiake He China	12	138 0.5×	50 0.5×	149 1.8×	68 0.8×	23 0.3×	31	411
Joe Palandra United States	15	360 1.2×	183 1.7×	282 3.3×	136 1.7×	24 0.3×	25	838
Frank W. Lee United States	13	184 0.6×	79 0.7×	173 2.0×	218 2.7×	29 0.4×	21	698
Takuro Niwa Japan	11	436 1.5×	207 1.9×	219 2.6×	188 2.3×	32 0.5×	16	824
Takehisa Matsumaru Japan	7	176 0.6×	75 0.7×	85 1.0×	96 1.2×	19 0.3×	12	354

Countries citing papers authored by Emi Kamiyama

Since Specialization

Citations

This map shows the geographic impact of Emi Kamiyama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emi Kamiyama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emi Kamiyama more than expected).

Fields of papers citing papers by Emi Kamiyama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emi Kamiyama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emi Kamiyama. The network helps show where Emi Kamiyama may publish in the future.

Co-authorship network of co-authors of Emi Kamiyama

This figure shows the co-authorship network connecting the top 25 collaborators of Emi Kamiyama. A scholar is included among the top collaborators of Emi Kamiyama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emi Kamiyama. Emi Kamiyama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kobayashi, Yoshimasa, Stefanie Hennig, Helen Kastrissios, et al.. (2023). Trastuzumab Deruxtecan Dosing in Human Epidermal Growth Factor Receptor 2‐Positive Gastric Cancer: Population Pharmacokinetic Modeling and Exposure–Response Analysis. The Journal of Clinical Pharmacology. 63(11). 1232–1243. 9 indexed citations

Shimomura, Akihiko, Toshimi Takano, Shunji Takahashi, et al.. (2022). Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2‐Positive or HER2‐Low Metastatic/Unresectable Breast Cancer. Clinical Pharmacology & Therapeutics. 113(1). 160–169. 11 indexed citations

Takahashi, Shunji, Masato Karayama, Masato Takahashi, et al.. (2021). Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. Clinical Cancer Research. 27(21). 5771–5780. 20 indexed citations

Saito, Kaku, et al.. (2020). Pharmacological and clinical study results of trastuzumab deruxtecan (T-DXd, ENHERTU<sup>®</sup>). Folia Pharmacologica Japonica. 156(1). 47–51. 2 indexed citations

Takahashi, Masato, Y-J. Bang, Masato Karayama, et al.. (2020). 147P Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan (T-DXd) with OATP1B/CYP3A inhibitors in patients with HER2-expressing advanced solid tumours. Annals of Oncology. 31. S68–S69. 1 indexed citations

Yamashita, Toshinari, Akihiko Shimomura, Toshimi Takano, et al.. (2020). Abstract P1-18-12: A phase 1, multicenter, open-label study to assess the effect of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) on QTc and pharmacokinetics in subjects with HER2-expressing metastatic and/or unresectable breast cancer. Cancer Research. 80(4_Supplement). P1–18. 8 indexed citations

Shitara, Kohei, Taroh Satoh, Satoru Iwasa, et al.. (2019). Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 7(1). 219–219. 22 indexed citations

Furuie, Hidetoshi, Emi Kamiyama, Akiko Watanabe, et al.. (2019). Effect of DS-8500a, a Novel G Protein-Coupled Receptor 119 Agonist, on the Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Subjects. Clinical Drug Investigation. 39(10). 967–978. 3 indexed citations

Satoh, Taroh, Kohei Shitara, Satoru Iwasa, et al.. (2019). Dose escalation and expansion cohort study for DS-8895a in patients with advanced solid tumors.. Journal of Clinical Oncology. 37(4_suppl). 99–99. 3 indexed citations

10.

Furuie, Hidetoshi, et al.. (2018). Safety and Pharmacokinetics of DS-8500a, a Novel GPR119 Agonist, After Multiple Oral Doses in Healthy Japanese Males. Clinical Drug Investigation. 38(6). 519–525. 9 indexed citations

11.

Ishizuka, Hitoshi, Takashi Taguchi, Kazuhito Shiosakai, et al.. (2018). Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study. Advances in Therapy. 35(8). 1239–1250. 2 indexed citations

12.

Shimizu, Toshio, Kimio Yonesaka, Hidetoshi Hayashi, et al.. (2017). Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 79(3). 489–495. 19 indexed citations

13.

Murai, Takahiro, Hideo Takakusa, Daisuke Nakai, et al.. (2014). Metabolism and disposition of [¹⁴C]tivantinib after oral administration to humans, dogs and rats. Xenobiotica. 44(11). 996–1008. 11 indexed citations

14.

Rozehnal, Veronika, Daisuke Nakai, Thomas M. Fischer, et al.. (2012). Human small intestinal and colonic tissue mounted in the Ussing chamber as a tool for characterizing the intestinal absorption of drugs. European Journal of Pharmaceutical Sciences. 46(5). 367–373. 120 indexed citations

15.

Kurihara, Atsushi, et al.. (2009). Pharmacokinetics and disposition of recombinant human osteoprotegerin (rhOPG) after intravenous administration in female fischer rats. Xenobiotica. 39(2). 113–124. 6 indexed citations

16.

Kamiyama, Emi, Daisuke Sugiyama, Daisuke Nakai, Shinichi Miura, & Osamu Okazaki. (2009). Culture Period-Dependent Change of Function and Expression of ATP-Binding Cassette Transporters in Caco-2 Cells. Drug Metabolism and Disposition. 37(9). 1956–1962. 20 indexed citations

17.

Kamiyama, Emi, Daisuke Nakai, Tsuyoshi Mikkaichi, Noriko Okudaira, & Osamu Okazaki. (2009). Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes. Life Sciences. 86(1-2). 52–58. 27 indexed citations

18.

Shibayama, Takahiro, et al.. (2007). Characterization of CS-023 (RO4908463), a Novel Parenteral Carbapenem Antibiotic, and Meropenem as Substrates of Human Renal Transporters. Drug Metabolism and Pharmacokinetics. 22(1). 41–47. 32 indexed citations

19.

Kamiyama, Emi, Yasushi Yoshigae, Atsushi Kasuya, et al.. (2007). Inhibitory Effects of Angiotensin Receptor Blockers on CYP2C9 Activity in Human Liver Microsomes. Drug Metabolism and Pharmacokinetics. 22(4). 267–275. 24 indexed citations

20.

Yamada, Akihiro, Kazuya Maeda, Emi Kamiyama, et al.. (2007). Multiple Human Isoforms of Drug Transporters Contribute to the Hepatic and Renal Transport of Olmesartan, a Selective Antagonist of the Angiotensin II AT1-Receptor. Drug Metabolism and Disposition. 35(12). 2166–2176. 111 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact